{"address1": "126 East Lincoln Avenue", "city": "Rahway", "state": "NJ", "zip": "07065", "country": "United States", "phone": "908 740 4000", "website": "https://www.merck.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil, Recombinant)/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, physician distributors and wholesalers, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, Ridgeback Biotherapeutics LP, as well Moderna, Inc. for the development and commercialization of V940, an investigational individualized neoantigen therapy. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.", "fullTimeEmployees": 70000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert M. Davis J.D.", "age": 56, "title": "Chairman, President & CEO", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 6076253, "fmt": "6.08M", "longFmt": "6,076,253"}, "exercisedValue": {"raw": 6766101, "fmt": "6.77M", "longFmt": "6,766,101"}, "unexercisedValue": {"raw": 18304676, "fmt": "18.3M", "longFmt": "18,304,676"}}, {"maxAge": 1, "name": "Ms. Caroline  Litchfield", "age": 54, "title": "Executive VP & CFO", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 2801844, "fmt": "2.8M", "longFmt": "2,801,844"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 8916697, "fmt": "8.92M", "longFmt": "8,916,697"}}, {"maxAge": 1, "name": "Ms. Jennifer L. Zachary", "age": 45, "title": "Executive VP & General Counsel", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 2732334, "fmt": "2.73M", "longFmt": "2,732,334"}, "exercisedValue": {"raw": 3461623, "fmt": "3.46M", "longFmt": "3,461,623"}, "unexercisedValue": {"raw": 4142191, "fmt": "4.14M", "longFmt": "4,142,191"}}, {"maxAge": 1, "name": "Dr. Dean Y. Li M.D., Ph.D.", "age": 61, "title": "Executive VP & President of Merck Research Laboratories", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 3442288, "fmt": "3.44M", "longFmt": "3,442,288"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3893921, "fmt": "3.89M", "longFmt": "3,893,921"}}, {"maxAge": 1, "name": "Mr. Chirfi  Guindo", "age": 57, "title": "Senior VP & Chief Marketing Officer for Merck Human Health", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 1541708, "fmt": "1.54M", "longFmt": "1,541,708"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dalton E. Smart III", "age": 57, "title": "Senior VP of Finance, Principal Accounting Officer & Global Controller", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David Michael Williams", "age": 54, "title": "Executive VP and Chief Information & Digital Officer", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter  Dannenbaum", "title": "Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lisa  LeCointe-Cephas", "age": 41, "title": "Senior VP and Chief Ethics & Compliance Officer", "yearBorn": 1982, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cristal N. Downing", "age": 53, "title": "Executive VP and Chief Communications & Public Affairs Officer", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 4, "shareHolderRightsRisk": 3, "overallRisk": 4, "governanceEpochDate": 1709078400, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 129.03, "open": 129.34, "dayLow": 127.7, "dayHigh": 129.4, "regularMarketPreviousClose": 129.03, "regularMarketOpen": 129.34, "regularMarketDayLow": 127.7, "regularMarketDayHigh": 129.4, "dividendRate": 3.08, "dividendYield": 0.024, "exDividendDate": 1710374400, "payoutRatio": 21.1429, "fiveYearAvgDividendYield": 2.9, "beta": 0.386, "trailingPE": 915.6429, "forwardPE": 13.134221, "volume": 5412173, "regularMarketVolume": 5412173, "averageVolume": 8395480, "averageVolume10days": 5935410, "averageDailyVolume10Day": 5935410, "bid": 128.18, "ask": 0.0, "bidSize": 800, "askSize": 1000, "marketCap": 324659118080, "fiftyTwoWeekLow": 99.14, "fiftyTwoWeekHigh": 130.24, "priceToSalesTrailing12Months": 5.400634, "fiftyDayAverage": 119.1116, "twoHundredDayAverage": 110.2281, "trailingAnnualDividendRate": 2.92, "trailingAnnualDividendYield": 0.022630397, "currency": "USD", "fromCurrency": null, "toCurrency": null, "lastMarket": null, "coinMarketCapLink": null, "algorithm": null, "tradeable": false, "enterpriseValue": 353888632832, "profitMargins": 0.00607, "floatShares": 2527831849, "sharesOutstanding": 2532640000, "sharesShort": 16818374, "sharesShortPriorMonth": 20814150, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0066000004, "heldPercentInsiders": 0.0007, "heldPercentInstitutions": 0.78595, "shortRatio": 2.2, "shortPercentOfFloat": 0.0066000004, "impliedSharesOutstanding": 2532640000, "category": null, "bookValue": 14.845, "priceToBook": 8.635231, "fundFamily": null, "legalType": null, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": 365000000, "trailingEps": 0.14, "forwardEps": 9.76, "pegRatio": 0.22, "lastSplitFactor": "1048:1000", "lastSplitDate": 1622678400, "enterpriseToRevenue": 5.887, "enterpriseToEbitda": 42.653, "52WeekChange": 0.20577514, "SandP52WeekChange": 0.27549195, "lastDividendValue": 0.77, "lastDividendDate": 1702512000, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "MRK", "underlyingSymbol": "MRK", "shortName": "Merck & Company, Inc.", "longName": "Merck & Co., Inc.", "firstTradeDateEpochUtc": -252322200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "3fd0c404-d9b9-32ea-a95e-f2db63766fb3", "messageBoardId": "finmb_288502", "gmtOffSetMilliseconds": -18000000, "currentPrice": 128.19, "targetHighPrice": 148.0, "targetLowPrice": 103.0, "targetMeanPrice": 134.18, "targetMedianPrice": 135.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 25, "totalCash": 7093000192, "totalCashPerShare": 2.801, "ebitda": 8296999936, "totalDebt": 36267999232, "quickRatio": 0.732, "currentRatio": 1.252, "totalRevenue": 60115001344, "debtToEquity": 96.368, "revenuePerShare": 23.695, "returnOnAssets": 0.02644, "returnOnEquity": 0.00901, "freeCashflow": 2130875008, "operatingCashflow": 13006000128, "revenueGrowth": 0.058, "grossMargins": 0.73526, "ebitdaMargins": 0.13802, "operatingMargins": 0.00082, "financialCurrency": "USD"}